Levodopa Pharmacotherapy in Parkinson's Disease

Levodopa, a precursor of dopamine, has served for over half a century as the most effective symptomatic treatment for Parkinson’s disease. Following oral administration, levodopa crosses the blood–brain barrier where it is decarboxylated to dopamine, compensating for nigrostriatal depletion. Co-administration of peripheral decarboxylase inhibitors preserves central availability and reduces systemic side effects, yet the short plasma half-life of levodopa contributes to motor fluctuations, on–off phenomena and dyskinesia. Recent advances aim to overcome these limitations through pharmacokinetic modelling, novel controlled-release formulations, prodrug design and nanocarrier systems to deliver levodopa more steadily or target it directly to the central nervous system. Optimising levodopa delivery has global significance, promising prolonged motor benefit, reduced complication rates and improved quality of life for millions of patients worldwide.

Research from Nature Portfolio

Physiologically based pharmacokinetic models have been used to challenge the notion that levodopa absorption occurs exclusively in the proximal small intestine. A validated mathematical framework demonstrated effective uptake throughout the entire small bowel and revealed that gastric release contributes to early plasma fluctuations. On the basis of these insights, researchers have proposed guidelines for next-generation controlled-release formulations that maintain stable levodopa concentrations, prolong therapeutic duration and reduce dosing frequency at different stages of Parkinson’s disease.

Levodopa Pharmacotherapy in Parkinson's Disease publication trend

The graph below shows the total number of articles in levodopa pharmacotherapy in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Levodopa: Aromatic amino acid precursor of dopamine used to restore central dopaminergic function.

Peripheral decarboxylase inhibitor: Agent (e.g. carbidopa) that blocks levodopa conversion outside the brain, enhancing central availability.

Controlled-release formulation: Drug delivery system designed to release an active compound at a predetermined rate for sustained therapeutic effect.

Motor fluctuations: Variability in symptom control reflecting peaks and troughs of levodopa plasma levels.

Dyskinesia: Involuntary, often choreiform movements arising from chronic levodopa therapy.

Nanoparticles: Submicron carriers engineered to protect drug cargo and facilitate targeted transport across biological barriers.

References

1. IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease. JAMA Neurology (2023).
2. Levodopa-loaded nanoparticles for the treatment of Parkinson's disease. Journal of Controlled Release (2023).
3. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease. Molecules (2017).
4. Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease. Scientific Reports (2023).